TEBillion will soon introduce its Branded Orders feature, an advanced and customised feature for TEB Cloud allowing users to be able to create and edit professional order forms. This will streamline a company’s order form creating process since the creation of personalised branded orders will be done within TEB’s software suite, and of course, using intelligent automation.
This feature is anticipated to also reduce business expense in paying for physical order forms as the branded quotes created from the TEB Cloud will then be ready to send to clients in one click of a button. This will also allow a company to scale growth in terms of responsive rate in sending orders and quotes, thanks to TEBillion’s excellent expertise in intelligent automation.
TEBillion is adamant in capitalising on intelligent automation and finding more new ways in improving the technology to help businesses around the world reach their goals with easy, fully integrated, and streamlined automation tools.
For more information about TEBillion’s products and services, contact:
Email: pr@tebillion.email
Website: www.tebillion.com
About TEBillion: TEBillion is a business automation software solutions company headquartered in the UK. Born in 2018, TEBillion aims to make high growth businesses successful with over a hundred handpicked partners serving customers, worldwide.
Let’s block ads! (Why?)
LambdaTest Tunnel boosts its security and performance with SOCKS5 proxy and HTTP/2 support, enabling secure,…
WUHAN, China--(BUSINESS WIRE)--With the acceleration of globalization, China automobile industry is facing new opportunities for…
NEW YORK--(BUSINESS WIRE)--FOX News Media, in partnership with the National Merit Scholarship Program, has selected…
SHANGHAI & SEOUL, South Korea & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shaperon, Inc. (Kosdaq: 378800), a biotechnology company…
Purchases Demonstrate Lessor’s Continued Strong Activity in Secondary Market DUBLIN--(BUSINESS WIRE)--#AndyCronin--CDB Aviation, a wholly owned…
Company in discussions with U.S. Food and Drug Administration regarding first-ever human clinical trial as…